French drug major Sanofi and the US unit of Israel’s Teva Pharmaceutical Industries have presented new, detailed results from the RELIEVE UCCD Phase IIb study of duvakitug, a human IgG1-λ2 monoclonal ...
Hosted on MSN9h
Hiking Arches National Park in the Summer: A Complete GuideEach year, hundreds of thousands of people visit Arches National Park to go hiking in the summer months, hoping for long, ...
About duvakitug Duvakitug is a potential best-in-class human IgG1-λ2 monoclonal antibody that targets tumor necrosis factor (TNF)-like ligand 1A (TL1A), also known as TNF superfamily member 15 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback